Related content

Retrospective analysis of capecitabine and oxaliplatin (XELOX) plus bevacizumab as a firstline treatment for Japanese patients with metastatic colorectal cancer

By                    

Molecular and Clinical Oncology, Vol. 2, Iss. 1, 2014-01 ,pp. : 134-138

Spandidos Publications

Access to resources Recommend Favorite

XELIRI regimen plus continuous treatment with bevacizumab is well-tolerated and effective in metastatic colorectal cancer patients in a secondline setting involving the sequential administration of XELOX and XELIRI

By                        

Molecular and Clinical Oncology, Vol. 2, Iss. 5, 2014-01 ,pp. : 827-832

Spandidos Publications

Access to resources Recommend Favorite

Tumor characteristics and metastatic sites may predict bevacizumab efficacy in the firstline treatment of metastatic colorectal cancer

By                  

Molecular and Clinical Oncology, Vol. 2, Iss. 1, 2014-01 ,pp. : 166-170

Spandidos Publications

Access to resources Recommend Favorite

Cancer and the treatment: Does it make sense to patients?

By Quinn Barry  

Hematology, Vol. 10, Iss. 1, 2005-09 ,pp. : 325-328

Maney Publishing

Access to resources Recommend Favorite

Influence of age on adenomatous polyposis coli and p53 mutation frequency in sporadic colorectal cancer—rarity of co-occurrence of mutations in APC, K-ras, and p53 genes

By Chiang Jy-Ming  

Virchows Archiv, Vol. 445, Iss. 5, 2004-11 ,pp. : 465-471

Springer Publishing Company

Access to resources Recommend Favorite